Sitala Bio

What Sitala Bio does

Sitala Bio Ltd is a privately held, pre-revenue biotechnology company based in Cambridge, United Kingdom, developing small-molecule drugs that modulate innate immunity and complement pathways to treat chronic inflammatory diseases. The company's scientific premise is that chronic, low-grade inflammation — driven by the evolved human immune system's response in the context of longer lifespans — is a root cause of disease, and that blocking the initiation and progression of this harmful inflammation can address both symptoms and underlying pathology.

The company's primary therapeutic focus is on neurodegenerative diseases such as Parkinson's and Alzheimer's, where dysfunction of brain immune cells (microglia and astrocytes) produces inflammatory molecules that prevent clearance of toxins like amyloid. Beyond neurodegeneration, the company positions its approach horizontally across systemic inflammatory conditions affecting musco-skeletal, lung, kidney, gut, skin, and eye organ systems. As of the input data, no named pharmaceutical products have been launched; the pipeline consists entirely of investigational medicines in preclinical or early-stage development.

Commercially, Sitala Bio is a founder-led company with Matt Cooper as CEO & Founder, operating with 11-50 employees from a single registered office at Unit D6, Grain House Mill Court, Great Shelford, Cambridge. The anticipated revenue model is one-time licensing of pharmaceutical products at a future commercialization stage; no pricing, customers, partners, or capital structure details are publicly disclosed. Distribution and marketing channels are not yet applicable given the pre-commercialization stage, and the company has no disclosed funding rounds, investors, or strategic alliances in the available data.

Name

Sitala Bio

Legal name

Sitala Bio Ltd

Website

https://sitala.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Sitala Bio Ltd is a Cambridge, UK-based pre-revenue biotechnology company developing small-molecule drugs that modulate innate immunity and complement pathways to treat chronic inflammatory diseases, with primary focus on neurodegenerative conditions such as Parkinson's and Alzheimer's.

Ownership category

akta.pro rank

Product category

Anti-Inflammatory Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Anti-inflammatory therapeutics
• Small-molecule drug development
• Neurodegenerative disease drugs
• Innate immunity modulation
• Complement pathway inhibitors

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical product revenue (anticipated): Pre-revenue biotech company developing novel anti-inflammatory medicines. Revenue anticipated from drug development and commercialization for treating neurodegenerative and inflammatory diseases.

Core offering

Sitala Bio Ltd develops small-molecule drugs designed to modulate innate immunity and complement pathways, targeting chronic low-grade inflammation that drives neurodegenerative diseases such as Parkinson's and Alzheimer's, as well as systemic inflammatory conditions affecting musco-skeletal, lung, kidney, gut, skin, and eye systems. The company is at the research and development stage, translating cutting-edge science into investigational therapies intended to block harmful inflammation at its source rather than only treating downstream symptoms.

Product overview

Sitala Bio is a biotechnology company dedicated to improving people's lives by delivering new medicines that block harmful inflammation. The company is in the research and development stage, focused on translating cutting-edge science and medical knowledge into new therapies for patients. Their therapeutic approach targets chronic, low-grade inflammation that drives neurodegenerative diseases (such as Parkinson's and Alzheimer's) and systemic inflammatory conditions affecting musco-skeletal, lung, kidney, gut, skin, eye, and other organ systems. The company has not yet launched any named pharmaceutical products or therapeutic modules; their current pipeline consists of investigational medicines in development.

Differentiator

Problem solved

Functional benefit

Products and services

• Investigational Anti-Inflammatory Small-Molecule Pipeline

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Equillium: Clinical-stage biotechnology company developing immunomodulatory therapies targeting inflammation at the cellular level for severe immuno-inflammatory disorders. Comparable as a small-molecule immunology/inflammation platform developer.
• Alector: Clinical-stage biotechnology company developing immune system-based therapies for neurodegenerative diseases, including progranulin and TREM2 programs. Highly comparable given shared focus on leveraging innate immunity to address neurodegeneration.
• Annexon Biosciences: Clinical-stage biotech developing therapeutics that block classical complement pathway activation (anti-C1q) for neurodegenerative and autoimmune indications including Guillain-Barré syndrome and geographic atrophy. Directly comparable as a complement-pathway drug developer targeting neuro inflammation.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases through multiple mechanisms including lysosomal function, glial biology, and inflammation. Comparable given shared neurodegenerative focus and biological emphasis on neuroinflammation pathways.
• IFM Therapeutics: Biotech focused on developing small molecules that modulate the innate immune system to treat inflammatory and autoimmune diseases (acquired by Bristol-Myers Squibb). Directly comparable for innate-immunity-targeted small-molecule drug development.
• Halia Therapeutics: Early-stage biotechnology company developing small-molecule therapies that target neuroinflammation and inflammasome pathways for neurological and inflammatory diseases. Directly comparable as a small-molecule neuroinflammation platform biotech.

Broad incumbents

• BioMarin Pharmaceutical: Established biopharmaceutical company developing therapies for rare genetic and neurological diseases including Parkinson's (gene therapy) and Batten disease. Comparable as a broader-incumbent neuroscience and rare-disease developer.
• Biogen: Major neurology-focused biopharmaceutical company with established Alzheimer's (aducanumab/lecanemab) and Parkinson's programs. Comparable as a dominant neurology incumbent pursuing neuroinflammation-adjacent mechanisms, though at vastly greater scale.
• Sage Therapeutics: CNS-focused biopharmaceutical company developing therapies for depression, epilepsy, and other CNS disorders. Comparable as a CNS specialty pharma developing novel neurotherapeutics, with broader pipeline focus than inflammation alone.
• Karuna Therapeutics: CNS-focused specialty pharmaceutical company developing therapies for schizophrenia and other CNS disorders (acquired by Bristol-Myers Squibb). Comparable as a CNS specialty pharma targeting underserved neurological indications, though with a different mechanistic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/sitala-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sitala Bio